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Positive selection in Europeans at the 2q21.3 locus harboring the lactase gene has been attributed to selection 
for the ability of adults to digest milk to survive famine in ancient times. However, the 2q21.3 locus is also 
associated with obesity and type 2 diabetes in humans, raising the possibility that additional genetic elements 
in the locus may have contributed to evolutionary adaptation to famine by promoting energy storage, but which 
now confer susceptibility to metabolic diseases. We show here that the miR-128-1 microRNA, located at the 
center of the positively selected locus, represents a crucial metabolic regulator in mammals. Antisense 
targeting and genetic ablation of miR-128-1 in mouse metabolic disease models result in increased energy 
expenditure and amelioration of high fat diet-induced obesity, and markedly improved glucose tolerance. A 
thrifty phenotype connected to miR-128-1-dependent energy storage may link ancient adaptation to famine and 




The extremely long (~1 Mb) haplotype on human chromosome 2 (2q21.3) represents a classic example of 
positive selection, where a large chromosome segment containing genetic variants has risen to high frequency 
among European populations over the last several thousand years, presumably due to selection for traits 
associated with a survival advantage (Bersaglieri et al., 2004; Field et al., 2016; Grossman et al., 2010; 
Grossman et al., 2013; Itan et al., 2009; Sabeti et al., 2002; Sabeti et al., 2007). The 2q21.3 locus harbors the 
lactase gene (LCT), encoding the enzyme lactase-phlorizin hydrolase, which hydrolyzes lactose and is 
expressed in the small intestine of infants allowing digestion of breast milk (Swallow, 2003). Intestinal 
expression of lactase is typically shut off after weaning in mammals. However, the long 2q21.3 haplotype in 
Europeans is strongly linked to expression of intestinal lactase into adulthood (termed lactase persistence, LP), 
allowing adult milk consumption (Gerbault et al., 2011; Itan et al., 2009; Segurel and Bon, 2017). The signature 
European LP single nucleotide polymorphism (SNP), rs4988235, is present in an intronic enhancer in the 
MCM6 gene, which is located just upstream of the LCT gene.  
 
LP has been postulated to have provided a selective advantage in nutrient-deprived populations and at higher 
latitudes with decreased sunlight due to supplementation of calcium and vitamin D3 to support proper bone 
formation and calcification (Flatz and Rotthauwe, 1973). However, other dietary sources might have provided 
sufficient sources of such nutrients (Itan et al., 2009). The current prevailing theory has posited that adult 
consumption of fresh milk among herding populations would have allowed additional calorie intake to produce 
a survival advantage during famines (Sverrisdottir et al., 2014). However, fresh milk is highly susceptible to 
microbial degradation, and from archeological records it is clear that farmers and herders in ancient times 
knew well how to preserve milk products through the generation of butter, yogurt and cheese products, where 
much of the lactose is removed or consumed (Curry, 2013; Salque et al., 2013; Segurel and Bon, 2017). 
Studies of ancient DNA have also shown that steppe populations lacked the rs4988235 LP SNP for thousands 
of years, yet were known to be herders and exhibited evidence of consumption of milk products (Jeong et al., 
2018; Mathiesen et al., 2015). Hence, individuals among herding populations, even those with moderate 
lactose intolerance, should have been able to consume stored milk products during most famines. 
 
Challenged by severe and prolonged famines that would generate strong selective pressure, increased energy 
efficiency and fat storage among human populations might also have provided a selective advantage for 
survival and propagation, perhaps in cooperation with the ability of adults to consume milk. While potentially 
beneficial in times of famine frequent after the transition from hunting and gathering to agriculture, this “thrifty 
gene” trait may now represent a metabolic maladaptation predisposing to obesity, insulin resistance and type 2 
diabetes (T2D) (Neel, 1962).  
 
Support for the possibility of a “thrifty” genotype-phenotype link comes from the fact that several genetic 
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variants across the locus have also been linked to metabolic abnormalities and diseases associated with 
decreased energy expenditure, such as obesity and T2D, as well as abnormal blood metabolites and lipids 
(Albuquerque et al., 2013; Almon et al., 2012; Bauer et al., 2011; Camporez et al., 2018; Corella et al., 2011; 
Gupta et al., 2013; Heard-Costa et al., 2009; Kettunen et al., 2010; Knowles et al., 2015; Ma et al., 2010; Rung 
et al., 2009; Scherag et al., 2010; Shin et al., 2014; Sladek et al., 2007; Suhre et al., 2011; Willer et al., 2013). 
For example, a meta-analysis of 31,720 individuals from diverse European populations showed a statistically 
significant (P=7.9 X 10-5) elevation of body mass index (BMI, kg/m2) associated with the positively selected 
allele of the rs4988235 SNP (Kettunen et al., 2010). Increased ectopic fat storage in liver and skeletal muscle 
represent strong risk factors for the development of insulin resistance and T2D (Shulman, 2014). In support of 
a link of the 2q21.3 locus to T2D, two genome-wide association studies (GWAS) coupled to metabolomics also 
reported an association of SNPs across this locus with altered levels of 1,5-anhydroglucitol (1,5-AG), a 
metabolite linked to abnormal glucose homeostasis and T2D (Kim and Park, 2013; Shin et al., 2014; Suhre et 
al., 2011). Hence, the long haplotype at 2q21.3 is linked to both LP and metabolic aberrations, which may 
reflect positive selection for multiple cooperative traits (ability to consume milk in adulthood and increased fat 
storage) that together could have conferred a strong survival advantage during severe famines.  
 
The genetic and molecular underpinnings for the association of the locus with obesity and T2D have remained 
obscure. It is possible that these additional associations with metabolic aberrations could be explained by one 
or multiple genetic elements present in the locus. While obesity has a clear genetic component in humans 
(Allison et al., 1996; Coleman, 1979; Maes et al., 1997; Rosenbaum and Leibel, 1998), meta-analysis of a 
number of genetic studies linking genetic loci to obesity failed to uncover strong support for single obesity 
genes producing a selective advantage (Speakman, 2013; Wang and Speakman, 2016), and there are no 
obvious candidate genes in the 2q21.3 locus. To date, the majority of genotype-phenotype studies in humans 
have focused on protein coding genes; however, microRNAs (miRNAs) have emerged as crucial regulators of 
the expression of hundreds of genes, often controlling the output of entire biological pathways (Ambros, 2004; 
Bartel, 2009, 2018). We and others have uncovered several miRNAs as crucial metabolic regulators (Goedeke 
et al., 2016; Najafi-Shoushtari et al., 2010; Rottiers and Näär, 2012). We previously employed an unbiased 
analysis of GWAS data from >188,000 individuals to identify miRNAs associated with abnormal blood lipids 
(Wagschal et al., 2015). These studies uncovered miR-128-1 as a critical regulator of circulating total 
cholesterol in vivo in mice (Wagschal et al., 2015). Importantly, miR-128-1 is an intronic miRNA present in the 
R3HDM1 gene, which is located at the center of the positively selected locus on human chromosome 2, 
approximately 200 kb from the LCT gene. Given the strong link of miR-128-1 to the GWAS association with 
cholesterol/lipid abnormalities (Wagschal et al., 2015), and the prediction that it might regulate expression of 
genes involved in metabolic control (www.targetscan.org), we sought to further evaluate whether miR-128-1 
represents a metabolic miRNA that could have contributed to the association of the long haplotype on human 




The 2q21.3 locus contains several selection signals in multiple species 
We began by examining the haplotype structure of 2q21.3 in Europeans, where we observed that there is a 
well-studied, strong selection signal across a long haplotype centered on the R3HDM1 gene (Figure 1A, Figure 
S1A). This selection signal is directly attributed to the LP phenotype associated with the previously reported 
tag SNP rs4988235. We note a strong metabolic association at the locus from our previous work detailing a 
lipid association with expression of miR-128-1 (Wagschal et al., 2015) present in the R3HDM1 gene. In light of 
this, along with the apparent selection signal associated with SNPs in R3HDM1 near miR-128-1 (e.g., 
rs1446585, Figure 1A), we examined the selection signal across species in more detail by performing a 
literature search to identify species exhibiting selection at the 2q21.3 syntenic locus, and if so, whether there is 
evidence for a metabolic association.  
 
Interestingly, the 2q21.3 syntenic locus in cattle has been shown in GWAS to be associated with increased 
feed efficiency (thrifty phenotype) and increased intramuscular fat (both are associated with the miR-128-1 
host gene R3HDM1), desirable traits in cattle breeding (Barendse et al., 2009; Bovine HapMap et al., 2009; 
Mei et al., 2018). There is also considerable genetic variation at the locus between breeds, potentially 
indicative of either artificial or natural selection (Bovine HapMap et al., 2009). Recent work indicates a 
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selection signal in canids as well, centered on the promoter of R3HDM1 (XP-EHH 1.02, p = 0.0056; Plassais et 
al., 2019). This selection signal on the derived allele is also associated with a 14.5 kg increase in body weight 
(p = 2.17 x 10-13) and is observed exclusively in large breeds with the “bulky” phenotype. Together, these data 
suggest a complex history of shared natural and artificial selection on multiple metabolic phenotypes at the 
2q21.3 locus (Figure 1B).  
 
We note that cattle and dogs are weaned and do not consume milk in adulthood. This makes it unlikely that LP 
would have contributed to the observed differences in body mass among bovine breeds and modern canids, 
which suggests other mechanisms might be at play. Given this, we performed a phenome-wide association 
study (PheWAS) using data from the UK Biobank, and found that European long haplotype 2q21.3 variants are 
associated with diverse body fat-related traits (Figure 1C), including overall body fat percentage/mass, trunk fat 
percentage/mass, and leg fat percentage/mass. This is supported by independent (non-UKBB) datasets, 
where we found robust associations at this locus with a number of metabolic traits, including strong 
associations with total cholesterol, LDL cholesterol, and 1,5-AG, and we verified the positive selection at the 
locus using the singleton density score (Field et al., 2016) (Figure S1B). We also examined other LP selection 
signals and found lipid associations consistent with the effects observed on the European haplotype (Figure 
S1C). We found tight linkage across ancient DNA samples in Europe, confirming the haplotype was selected 
as a whole (Mathieson and Mathieson, 2018) (Figure 1D), and consistent with the observed shift in allele 
frequencies across the locus in present-day Europeans (Figure S1D). 
 
To explore which cell types are most likely responsible for the association with metabolic traits at this locus, we 
considered variants at the whole extended haplotype. Analyzing chromatin state maps across 127 human cell 
types from the Roadmap (Roadmap Epigenomics et al., 2015) and ENCODE (Hoffman et al., 2013) consortia 
(Figure 2A), we found that the 2q21.3 locus is characterized by enhancer-associated marks in blood, fetal 
brain, and mesenchymal lineages, including adipocytes and their progenitor cells. Using chromatin 
conformation data in lymphoblastoid cells (Mumbach et al., 2016; Rao et al., 2014), we discovered that the 
rs1438307 variant is located on the edge of a topological associated domain (TAD) which contains the miR-
128-1, ZRANB3, and R3HDM1 gene promoters (Figure 2B; Figure S2B), as well as a larger domain further 
containing RAB3GAP1 (Figure 2C). We thus considered the possibility that the positive selection haplotype 
might be associated with altered chromatin accessibility and expression across the locus (Flavahan et al., 
2016; Hnisz et al., 2016). 
 
We tested for differences of binding of the chromatin boundary factor CTCF to the haplotype and found that 
CTCF indeed preferentially binds the derived T allele of rs1438307 (Figure 2D, S2A). Because of the relatively 
low read depth at the canonical rs4988235, we were unable to test for allelic bias at this particular position, and 
our findings should only indicate that the haplotype as a whole alters CTCF binding. The T allele further 
associated with increased expression of R3HDM1 as well as UBXN4, ZRANB3, and RAB3GAP1, but not 
flanking genes outside the positively selected region such as CXCR4 (Figure 2D). In addition, we found a 
substantial allelic bias of rs1438307 for histone H3 lysine 4 trimethylation (H3K4me3; a histone mark 
associated with open chromatin and active transcription) across cell types (Figure S2C), supporting the notion 
that increased accessibility was associated with the T allele. 
 
Consistent with our hypothesis that chromatin accessibility and gene expression across the locus is 
programmed by the genetic architecture, we found that expression of the miR-128-1 host gene R3HDM1 is 
strongly linked to the expression of the MCM6 gene in 984 cell lines in the GDSC database (GDSC, 
CellMinerCDB; https://discover.nci.nih.gov/cellminercdb/) (r = 0.488, p = 3.44e-60, Figure 2E), indicative of 
concerted differential gene regulation at the locus. Furthermore, using expression data from 940 cell lines in 
the CCLE database (CCLE, CellMinerCDB), we found that miR-128-1 expression also correlated with the 
expression of the host gene R3HDM1 (r = 0.337, p = 2.05e-26, Figure 2F). Lastly, we confirmed that the 
rs1438307 T allele associates with higher DNase I accessibility compared to the G allele at the miR-128-1 
promoter, just upstream of the sequence encoding the miRNA itself (Figure S2D). These results link rs1438307 
to altered chromatin architecture and accessibility leading to coordinated expression changes across the locus 
through epigenetic regulation. 
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To assess whether the miR-128-1 haplotype has an effect on miR-128-1 expression, we conducted an 
expression quantitative trait locus (eQTL) analysis in subcutaneous and visceral white adipose tissues (WAT) 
from 64 derived homozygotes, 76 heterozygotes, and 39 ancestral homozygotes from a European cohort. We 
found a subtle haplotype-specific differential expression of miR-128-1 (F-test p = 0.06; Figure S3A, B).  We 
observed this trend to be depot-specific, with visceral WAT expression being somewhat higher than in 
subcutaneous WAT in both our discovery and replication cohorts (1.8-fold, p = 1.2e-4 and 1.8-fold, p = 4.7e-3, 
Figure S3A, B). When evaluating the effect of the haplotype tagging variant rs1446585, there was a trend 
towards the G allele lowering miR-128-1 expression in three cohorts (Figure S3C). We further noted a 
significant association of miR-128-1 levels with elevated fasting glucose (beta = 0.345, p = 0.0015, Figure 
S3D), HbA1c levels (beta = 0.135, p = 0.028, Figure S3E), and triacylglycerol (TAG)/high-density lipoprotein 
(HDL) ratio (all associated with the Metabolic Syndrome; beta = 0.071, p = 0.044, Figure S3F) in our well-
annotated adipose tissue replication cohort (n = 31). Using data from the METSIM study (n = 200, Civelek et 
al., 2013), where mature miR-128 expression was measured with high-throughput sequencing, we confirmed 
the significant association between log-transformed miR-128 expression and serum fasting glucose levels 
(beta = 0.47, p = 0.01; Figure S3G). When examining a time course of human adipocyte differentiation, we 
found that miR-128-1 expression increases steadily throughout differentiation (Figure S3H), consistent with a 
mechanism active in mature adipocytes. Finally, we examined the FINEMAP-derived posterior estimates 
(https://www.finucanelab.org/data) and found an association block next to rs4988235 for which the derived 
allele of rs1446585 was a strong causal candidate for decreased ApoA1 and HDL-cholesterol levels (Figure 
S3I), but which was not associated with other metabolic traits. 
 
Together, we show that the European long haplotype at 2q21.3 is associated with a locus-wide increased 
chromatin accessibility, which leads to coordinated elevated expression of miR-128-1 and co-expressed genes 
at the locus. Given the increased expression of miR-128-1 through differentiation and depot-specific 
expression, we implicate adipose and possibly other metabolic tissues in this effect. Altogether, our data 
provide evidence that the 2q21.3 locus associates with metabolic traits. 
 
Anti-miR oligonucleotides promote increased energy expenditure and protection from diet-induced 
obesity  
To explore whether miR-128-1 plays a role in regulating energy expenditure and metabolic control, we initially 
tested miR-128-1 inhibition by anti-miR oligonucleotides in high-fat diet (HFD)-fed male C57BL/6J mice, an 
established diet-induced obesity (DIO) model (Lee et al., 2014). Treatment with once-weekly subcutaneous 
injections of 10 mg/kg of a locked nucleic acid (LNA)-modified anti-miR targeting miR-128-1 (miR-128-1 ASO) 
over 16 weeks in male DIO mice potently reduced miR-128-1 levels in metabolic tissues (e.g., liver; Figure 
S4A), which was accompanied by strongly reduced weight gain on the HFD, being apparent already two weeks 
after treatment initiation (Figure 3A, B). This was not due to decreased food intake; if anything, the mice, at 
least temporarily, consumed more food in response to anti-miR-128-1 treatment (Figure S4B), possibly related 
to compensatory mechanisms (Soukas et al., 2000). In agreement with our previous studies in Apoe-/- mice 
(Wagschal et al., 2015), treatment with anti-miR-128-1 resulted in markedly lowered circulating total cholesterol 
and TAG levels (Figure S4C, D). Body composition studies with 1H nuclear magnetic resonance (EchoMRI) 
revealed substantially decreased fat stores (>25%; P<0.05) after 15 weeks of treatment, but no significant 
effect on lean mass (Figure 3C). Accordingly, the visceral (epididymal) and subcutaneous (inguinal) fat pads 
were markedly smaller in anti-miR-128-1 treated animals as compared with control anti-miR treated mice 
(Figure 3D). Livers of anti-miR-128-1 treated mice also exhibited smaller size and were less pale, indicative of 
decreased hepatic lipid accumulation as compared to controls (Figure 3D). In contrast, the inter-scapular 
brown adipose tissue (BAT) depot, which plays a key role in thermogenesis and regulation of energy 
expenditure, exhibited increased brown adipose appearance (less fat accumulation/hypertrophy and increased 
mitochondrial content) in response to anti-miR-128-1 treatment (Figure 3D). 
   
Next, we evaluated the phenotypic effects of anti-miR-128-1 treatment in metabolic tissues (e.g., BAT, white 
adipose tissue (WAT), liver and skeletal muscle). In accordance with the gross appearance of the BAT depot, 
histological analysis revealed strongly decreased accumulation of fat, and markedly increased staining with an 
antibody recognizing the BAT hallmark, uncoupling protein 1 (Ucp1), in immunohistological analysis of anti-
miR-128-1 treated mice as compared with control treated mice (Figure 3E). Evaluation of gene expression 
changes in BAT revealed that anti-miR-128-1 treatment resulted in an increase in mRNA levels of several 
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predicted and verified direct targets of miR-128-1 (www.targetscan.org), including Prdm16, Ppargc1a, and 
Ppara, which are known to promote BAT cell fate determination and stimulate mitochondrial biogenesis and 
fatty acid -oxidation (FAO) (Ohno et al., 2013; Seale et al., 2011), as well as the expression of a number of 
mitochondrial and energy expenditure genes such as Dio2, Cidea, and Cox family members (Cannon and 
Nedergaard, 2004; Seale et al., 2007) (Figure 3F and Figure S4E).  
  
WAT hypertrophy, as well as inflammatory cell infiltration in WAT, are frequently associated with obesity and 
T2D (Sun et al., 2011a; Wensveen et al., 2015). We found that anti-miR-128-1 treatment of DIO mice led to 
smaller fat cells and decreased “crown-like” accumulation of macrophages surrounding the fat cells in 
epididymal WAT (Figure 3G), evidence of a positive effect of anti-miR-128-1 treatment on WAT fat storage and 
inflammation. In agreement, the expression of Pparg and Adipoq (adiponectin), two hallmark genes of healthy 
fat (Ohno et al., 2012; Rosen and Spiegelman, 2014), was increased in epididymal WAT in response to anti-
miR-128-1 treatment, whereas genes encoding inflammatory cytokines and macrophage markers such as 
Tnfa, Il-1b, Il-6 and Mcp1 (Hotamisligil et al., 1993; Odegaard and Chawla, 2008; Weisberg et al., 2003) were 
downregulated (Figure 3H and Figure S4F).  
Metabolic dysfunction associated with obesity and T2D typically also manifests as excess fat accumulation and 
inflammation in the liver, hallmarks of nonalcoholic fatty liver disease and steatohepatitis (NAFLD/NASH) 
(Shulman, 2000, Suzuki and Diehl, 2017). We found that anti-miR-128-1 treatment caused a dramatic 
decrease in hepatic lipid accumulation and inflammation in DIO mice (Figure 3I). The marked reduction in liver 
fat correlated with strongly decreased levels of the Srebp1 transcription factor, a master regulator of lipogenic 
gene expression (Horton et al., 2002). Accordingly, expression of Srebp1 target genes encoding lipid synthesis 
enzymes (Acc1 and Fasn) was coordinately downregulated in response to anti-miR-128-1 treatment (Figure 3J 
and Figure S4G). We also observed a decrease in the expression of genes linked to adipogenesis and fat 
storage (Pparg and Fabp4) and increased expression of Ppara, encoding a transcriptional regulator of genes 
involved in FAO (Pawlak et al., 2015) (Figure 3J). 
  
Skeletal muscle represents another highly metabolically active tissue, and anti-miR-128-1 treated DIO mice 
also show potent stimulation of genes encoding proteins broadly involved in controlling cellular metabolic 
circuits, such as Ppar, Pgc-1, Ampk2, Ucp3 and many others in this tissue as compared to controls (Figure 
3K-M). Taken together, these findings support the notion that miR-128-1 acts to coordinately restrict gene 
expression programs governing energy expenditure across multiple metabolically active organs and tissues. 
Accordingly, metabolic cage studies revealed that inhibition of miR-128-1 caused markedly enhanced energy 
expenditure, without significantly affecting locomotor activity levels (Figure 3N and Figure S4H-J). Consistent 
with miR-128-1 mediating these metabolic effects directly through regulating expression of target genes 
involved in metabolic control, we found that miR-128-1 negatively regulates expression of luciferase reporters 
fused with 3’ UTRs of human PPARGC1, PPARG, PPARA and PRDM16, with effects abolished by mutation of 
conserved miR-128-1 target sites (Figure S4K). 
 
miR-128-1 is a key regulator of glucose homeostasis and insulin sensitivity 
Obesity and ectopic fat deposition in liver and skeletal muscle is frequently linked to insulin resistance and poor 
glucose control, and is a major risk factor for the development of T2D (Shulman, 2000, Kahn et al., 2006). DIO 
mice present with hyperglycemia and moderate insulin resistance; these abnormal metabolic traits were 
significantly ameliorated by anti-miR-128-1 treatment as revealed by glucose and insulin tolerance tests 
(Figure 3O, P). To further ascertain the role of miR-128-1 in obesity-associated glucose abnormalities we 
carried out hyperinsulinemic-euglycemic clamp studies (Kim, 2009; Perry et al., 2015) in DIO mice treated with 
anti-miR-128-1 and control anti-miR. Accompanying the decreased body weight and lowered fat mass (Figure 
4A, B), anti-miR-128-1-treated mice exhibited marked improvements in insulin-stimulated whole-body glucose 
metabolism, as revealed by substantially increased glucose infusion rates required to maintain euglycemia 
during the clamp (Figure 4C-E). This improvement in whole body insulin-stimulated glucose metabolism could 
be attributed to marked improvements in muscle glucose uptake as reflected by increased 2-deoxyglucose 
uptake in skeletal muscle (Figure 4F) as well as increased hepatic insulin responsiveness as reflected by 
greater suppression of hepatic glucose production during the clamp (Figure 4G). In addition, anti-miR-128-1 
treatment also manifested increased WAT insulin sensitivity as reflected by increased 2-deoxyglucose uptake 
in WAT (Figure 4F) and increased suppression of non-esterified fatty acid (NEFA) release from WAT (Figure 
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4H) during the clamp, both of which are hallmarks of T2D and contributors to increased rates of hepatic 
gluconeogenesis (Karpe et al., 2011; Thabit et al., 2014, Perry et al., 2015). These results together 
demonstrate a key role for miR-128-1 in modulating metabolic circuits that govern glucose homeostasis, 
consistent with the genetic link of the miR-128-1 locus to T2D.  
 
Role of miR-128-1 in metabolic dysregulation in leptin-deficient ob/ob mice 
Next, we sought to evaluate whether miR-128-1 might also contribute to metabolic abnormalities in the classic 
leptin-deficient ob/ob genetic obesity mouse model (Wang et al., 2014). These mice exhibit profound 
hyperphagia due to the lack of the satiety hormone leptin, which is normally secreted from WAT in response to 
feeding and acts in the hypothalamus to suppress feeding behavior (Wang et al., 2014). Treatment of ob/ob 
mice fed a standard chow diet with anti-miR-128-1 resulted in a modest but significant decrease in body weight 
and overall fat mass, and decreased size of liver and visceral (epididymal) WAT depots (Figure S5A, B).  
Metabolic cage analysis demonstrated markedly elevated energy expenditure in response to anti-miR-128-1 
treatment as compared with control anti-miR treatment (Figure S5C). Accordingly, histological and molecular 
analyses of BAT revealed decreased fat accumulation and strongly increased expression of BAT markers and 
energy expenditure genes such as Prdm16, Ppargc1a, Ppara (all direct targets of miR-128-1; Figure S4K) as 
well as Ucp1, Cidea, Dio2 and Elovl3 (Figure S5D, E), indicative of improved BAT function. We also observed 
decreased adipocyte hypertrophy in the subcutaneous (inguinal) WAT depot, accompanied by elevated 
expression of browning markers and energy expenditure genes (e.g., Prdm16, Ppargc1a, Ppara, Ucp1) in 
animals treated with anti-miR-128-1, consistent with browning or beigeing of subcutaneous WAT depots 
(Kajimura et al., 2015). Additionally, expression of Srebf1 and lipogenic genes (Acc1 and Fasn) was 
diminished, and expression of inflammatory cytokines (Tnf and Il1b) was lowered (Figure S5F, G). Anti-miR-
128-1 treatment also resulted in improved hepatic steatosis and led to decreased liver expression of markers 
of inflammation and lipogenesis in ob/ob mice (Figure S5H, I). These beneficial metabolic effects were 
accompanied by markedly improved glucose tolerance and insulin sensitivity in anti-miR-128-1-treated ob/ob 
mice (Figure S5J, K), confirming a potent metabolic regulatory function of miR-128-1 in both diet-induced and 
genetic obesity and T2D models. 
 
Whole animal genetic ablation of miR-128-1 confirms its “thrifty” role in DIO mice 
To confirm the role of miR-128-1 in controlling energy expenditure in vivo, we next analyzed the effects of miR-
128-1 whole animal genetic ablation (Tan et al., 2013; Wark et al., 2017) in mice using the DIO model. Most 
KO animals were viable and fertile, with no obvious developmental, physiological or behavioral phenotypes. 
Upon challenge with a HFD, the miR-128-1 KO mice exhibited significantly decreased weight gain as 
compared with WT littermates (Figure 5A). After 12 weeks on the HFD, the miR-128-1 KO mice WAT depots 
were >60% smaller that WT controls, as revealed by EchoMRI (Figure 5B). Metabolic cage studies also 
showed that miR-128-1 KO mice exhibit markedly increased energy expenditure, without apparent effect on 
activity (Figure 5C, D). Consistently, the miR-128-1 KO mice were significantly more tolerant to cold exposure 
as compared with WT littermates (Figure 5E). Examination of the inter-scapular BAT depot revealed strongly 
decreased intracellular fat (Figure 5F), and primary BAT cells isolated from miR-128-1 KO mice exhibited 
greatly increased mitochondrial oxygen consumption rate and energy expenditure, as shown by Seahorse 
studies (Figure 5G), as well as elevated expression of BAT and energy expenditure marker genes such as 
Prdm16, Ppargc1a, and Ppargc1b, and Ucp1 (Figure S6). Beneficial effects on metabolic gene expression 
were also observed in WAT, skeletal muscle and liver of miR-128-1 KO mice (Figure S6). Finally, similar to the 
results in DIO mice treated with anti-miR-128-1, the HFD-fed miR-128-1 KO mice exhibited markedly improved 
glucose homeostasis and response to insulin (Figure 5H, I). These findings strongly support the notion that 
miR-128-1 represents a crucial regulator of whole animal metabolism by acting as a “thrifty” miRNA to 
suppress energy expenditure through apparent effects in multiple metabolic tissues, such as WAT, BAT, liver 
and skeletal muscle. 
 
miR-128-1 modulates white adipose differentiation and function  
Next, we further investigated the molecular mechanism(s) of miR-128-1 regulation of cellular metabolism, and 
determined whether the regulatory effects observed in metabolic tissues are cell autonomous. Introduction of 
excess miR-128-1 precursor into human abdominal subcutaneous WAT-derived pre-adipocytes resulted in 
decreased adipogenesis in response to a differentiation cocktail, with lowered numbers of mature, fat-storing 
adipocytes, and decreased expression of white adipocyte differentiation markers such as PPARG, CEBPA, 
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FABP4, PPARGC1A and PPARA, as well as the adipokines adiponectin (ADIPOQ) and leptin (LEP) (Figure 
6A, B). Conversely, treatment of pre-adipocytes with anti-miR-128-1 caused increased adipocyte differentiation 
and elevated expression of genes associated with mature WAT (Figure 6C, D). In particular, the expression of 
adiponectin and leptin was markedly affected by changing miR-128-1 levels (both mRNAs are predicted miR-
128-1 targets in humans but not in mice; www.targetscan.org). These adipokines have been shown to 
represent hallmarks of healthy WAT and exert beneficial metabolic effects in multiple tissues (Meier and 
Gressner, 2004). In accord with the gene expression data, we observed potent regulation by miR-128-1 of 
leptin and adiponectin secreted into the culture medium (Figure 6E, F). In addition to being targets of miR-128-
1, it is likely that leptin and adiponectin are induced indirectly in WAT through the miR-128-1 target and pro-
adipogenesis transcription factor PPAR. We also verified that altering miR-128-1 levels had concordant 
effects on levels of target proteins, such as AMPK2, PGC-1, SIRT1, PPAR, PPAR, INSR and IRS1 
(Figure 6G). In keeping with the known role of AMPK2 as a key stress kinase regulator of the lipogenic 
enzyme ACC1 by direct inhibitory phosphorylation, altered AMPK2 levels in response to miR-128-1 
manipulations resulted in corresponding changes in ACC1 phosphorylation status (Figure 6G). A number of 
miR-128-1 targets (e.g., AMPK2, PGC-1, SIRT1, PPAR) regulate FAO, and we found that miR-128-1 
overexpression decreased, whereas miR-128-1 inhibition increased, FAO in human WAT-derived adipocytes 
(Figure 6H, I). These findings are consistent with in vivo data from WAT in DIO mice, where anti-miR-128-1 
treatment results in decreased WAT hypertrophy, accompanied by lowered expression of Srebf1 and lipogenic 
target genes (Figure S7A-D), as well as significant de-repression of Pparg, Adipoq, and Ppargc1a, and 
elevated expression of Prdm16, Ppara and Ucp1 (Figure S7E-J), suggesting increased browning of WAT in 
response to inhibition of miR-128-1 in DIO mice.  
 
miR-128-1 inhibits brown adipose cell fate and energy expenditure 
Due to the marked positive effects on BAT differentiation and energy expenditure observed in DIO and ob/ob 
mice treated with anti-miR-128-1 and in the HFD-fed miR-128-1 KO mice, we evaluated the molecular 
mechanism and functional importance of miR-128-1 in regulating brown adipose cell differentiation in vitro. 
Primary brown pre-adipocytes isolated from the inter-scapular BAT depot of Day 1 newborn miR-128-1 WT 
and KO mice were induced to differentiate and then stained with Oil-Red O as a marker of mature adipocyte 
differentiation. We found that loss of miR-128-1 resulted in strongly increased capacity to differentiate into 
mature brown adipocytes (Figure 7A). This was supported by results from Seahorse analysis showing elevated 
energy expenditure in brown adipocytes from miR-128-1 null mice (Figure 7B). Moreover, expression of brown 
adipose hallmark genes (Prdm16, Ucp1) as well as transcription factors and co-activators involved in adipose 
cell fate determination and regulation of gene expression programs governing lipid homeostasis and energy 
expenditure (Pparg, Ppara, and Ppargc1a) was elevated in differentiated brown adipocytes from miR-128-1 KO 
mice as compared with controls (Figure 7C-G). We also examined acute effects of introducing pre-miR-128-1 
in already differentiated WT brown adipocytes, in the presence or absence of the brown adipose inducer 
dbcAMP (Uldry et al., 2006). Our studies revealed potent suppression of direct (e.g., Prdm16, Ppargc1a, 
Ppara) and indirect (e.g., Ucp1 and Cidea) miR-128-1 targets involved in brown adipocyte function and lipid 
homeostasis and energy expenditure programs, even in the presence of dbcAMP (Figure 7H-J). Moreover, 
introduction of anti-miR-128-1 into mature, differentiated mouse brown adipocytes resulted in marked de-
repression of the expression of these genes (Figure 7K-M). Cell lineage tracing studies in vivo have revealed 
that brown adipocytes can derive from a Myf5-positive skeletal muscle precursor lineage (Sanchez-Gurmaches 
and Guertin, 2014; Seale et al., 2008). In vitro studies have also shown that the mouse C2C12 muscle 
precursor cell line can be differentiated into brown adipocytes (Sun et al., 2011b). We found that anti-miR-128-
1 treatment of C2C12 cells markedly promoted brown lineage commitment and differentiation into mature 
brown adipocytes, as judged by elevated Oil-Red O staining and increased expression of pan-adipocyte 
(Pparg, aP2, Cebpa, Adipoq) and brown adipose marker genes (Prdm16, Ucp1, Cidea, Elovl3, Ppargc1a, 
Ppara), but decreased expression of mature myocyte genes (Figure 7N-R). In accord, induction of brown 
adipocyte differentiation of C2C12 cells in response to inhibition of miR-128-1 was accompanied by elevated 
FAO and increased energy expenditure, functional hallmarks of mature brown adipocytes (Figure 7S, T). 
Taken together, these findings provide strong support for a direct cell autonomous role of miR-128-1 in 







Positive selection of a long (~1 Mb) haplotype on human chromosome 2 in Europeans, harboring the lactase 
(LCT) gene, has been thought to be solely due to lactase persistence (LP), allowing adult milk consumption. 
The ability to consume fresh milk beyond infancy may indeed have provided a selective advantage in ancient 
populations faced with poor nutrition and famine. However, this hypothesis may not fully account for the 
remarkably strong positive selection signature resulting in the long haplotype in this genomic locus. For 
example, studies of ancient DNA and extensive archeological records have shown that herders consumed milk 
products for thousands of years before the emergence of the LP haplotype/phenotype around 4KY ago (Jeong 
et al., 2018, Mathiesen et al., 2015), challenging the importance of fresh milk consumption as a potential driver 
of evolutionary adaptation to famine. Importantly, the European long haplotype is also associated with 
metabolic disorders such as obesity and T2D. It has been difficult, however, to reconcile LP with these 
metabolic abnormalities, and based on our data presented here, we propose that the miR-128-1 miRNA 
located in the center of the positively selected locus might contribute to some of these links. Indeed, our results 
showing concordance of the positive selection haplotype with genetic associations of the miR-128-1 locus to 
obesity and T2D, as well as the phenome-wide association study using UK Biobank data revealing association 
of 2q21.3 variants with diverse body fat-related traits, might be consistent with metabolic regulation by miR-
128-1. However, it does not rule out the possibility that some of the signal is due to LCT in humans. Self-
reported fresh milk intake, depending on milk fat content, however has a complex relationship with body fat 
phenotypes in the UK Biobank data set, and will require further in-depth study.  
 
In support of the links of the locus to metabolic phenotypes, we highlight data suggesting that the syntenic 
genomic region near R3HDM1/miR-128-1 in cattle has been under positive selection, and is associated with 
feed efficiency and intramuscular fat, thrifty metabolic traits selected for in certain cattle breeds (Barendse et 
al., 2009; Bovine HapMap et al., 2009; Mei et al., 2018). Moreover, dog breeds exhibiting a “bulky” (large 
size/excess backfat) phenotype have characteristic SNPs in the promoter of the miR-128-1 host gene 
R3HDM1 (Plassais et al., 2019). Cattle and canines are weaned and do not consume fresh milk in adulthood. 
While these finding may be consistent with our data showing that miR-128-1 regulates metabolic circuits and 
promotes fat storage in mammals, further studies will be needed to assess whether miR-128-1 contributes to 
the genetically selected phenotypes in cattle and dogs. 
 
Our mechanistic analyses reveal that the European long 2q21.3 haplotype is associated with increased 
chromatin accessibility and elevated transcriptional activity throughout the locus, likely in part due to altered 
CTCF chromatin boundary factor occupancy, contributing to the changes in miR-128-1/gene expression across 
the locus. Although the derived allele of the rs4988235 SNP present in the MCM6 intronic enhancer is strongly 
correlated with increased expression of the nearby LCT gene, it is possible the activity from this enhancer, in 
the context of the overall chromatin architecture of the European long haplotype, is also linked to the 
expression of other genes in the locus, as well as miR-128-1. Future studies are needed to address this and 
determine which variants and targets drive the associations. 
 
Intervention studies with anti-miR treatment targeting miR-128-1 in mouse obesity models suggest that miR-
128-1 represents a crucial regulator of metabolism by suppressing the expression of a number of genes 
encoding critical metabolic regulators in multiple metabolic tissues. Indeed, antagonism or ablation of miR-128-
1 either by antisense targeting or whole animal KO results in markedly increased energy expenditure, 
accompanied by reduced fat mass and improved whole body glucose metabolism, which could be attributed to 
increased liver, muscle and adipose tissue insulin sensitivity. Based on these observations, along with human 
GWAS data, we propose that elevated levels of miR-128-1 in metabolic tissues may reduce energy 
expenditure and promote increased fat storage in humans as well.  
 
Taken together, our data showing a key role for miR-128-1 in programming a metabolic switch from energy 
expenditure to energy storage and the links of the miR-128-1 genomic locus to positive selection and abnormal 
metabolism complement the role of lactase persistence at the locus. Indeed, altered expression of miR-128-1 
could have been beneficial in ancient times, but presently, with persistent calorie abundance, may constitute a 
metabolic maladaptation, predisposing to obesity and T2D. Hence, miR-128-1 may represent a therapeutic 
target for the treatment of metabolic diseases such as obesity and T2D. 
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Study Limitations 
There are many limitations to this work. Comprehensive measures of selection and genome-wide association 
studies are not available for most species, and fewer still have well-powered GWA studies of metabolic traits. 
This limits our ability to evaluate the presence of, and associations with, selection at the 2q21.3 locus. In 
addition, the long European haplotype contains numerous variants, and determining which are causal for the 
observed associations is an area of future study. Direct perturbation will also enable more comprehensive 
characterization of the epigenetic and transcriptomic consequences of these variants, which should help 
determine the gene(s) and/or microRNA(s) attributable to the various observed phenotypes associated with the 
locus and disentangle population history, environmental correlates, and single-variant effects. Furthermore, 
because miR-128-1 regulates the expression of many metabolic genes coordinately in multiple metabolically 
active tissues, it presents a formidable challenge to fully elucidate the mechanistic links of miR-128-1 to 
specific targets and in specific tissues. Finally, mouse models are an important step in understanding the 
mechanistic basis of miR-128-1 metabolic control, however, clinical studies will be critical to applying this 
knowledge to human disease alleviation. 
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Figure 1. Selection at the 2q21.3 locus in mammals.  
(A) A strong signal of positive selection is present at the 2q21.3 locus, evaluated using the Composite of 
Multiple Signals (CMS, Grossman et al., 2010). (B) Selection at 2q21.3 across mammals. There is evidence for 
selection on metabolic and anthropomorphic traits in dogs, cows, and humans. Relative locations annotated on 
the basis of lead SNPs in other species transferred to human GRCh37. (C) PheWAS of UK Biobank traits at 
rs1438307. Aggregated traits show a strong effect primarily on body composition and adiposity, with a smaller 
effect on cholesterol. (D) Ancient DNA from different ancient European populations reveals that that a shared 
selection event is present at the locus, starting in the Steppe ancestry around 4KY (Mathieson and Mathieson, 
2018). 
 
Figure 2. The 2q21.3 regulatory circuitry in humans. 
(A) Chromatin state maps from 127 cell types for the region surrounding miR-128-1. (B) Hi-C (GM12878) 
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indicates a stable chromatin domain whose boundary coincides with rs1438307. (C) Wider view of the 
topological domain reveals a larger domain structure also encompassing RAB3GAP1. A further domain 
contains DARS and CXCR4. (D) The intensity of the CTCF peak of interest and the expression of R3HDM1 
gene are strongly increased in the ENCODE cell lines with the variant locus rs1438307. Boxplots of the 
distributions of CTCF ChIP-seq enrichment near the TSS of UBXN4 gene (left) and the expression of R3HDM1 
(right) for the ENCODE samples with two different variants of rs1438307 (T, red vs G, blue). (E) Data from 
CellMinerCDB, derived from GDSC, show that expression of genes in the locus, spanned by R3HDM1 and 
MCM6, are highly correlated. (F) The expression of miR-128-1 is highly correlated with the expression of the 
host gene R3HDM1 (CCLE). 
 
Figure 3. Inhibition of miR-128-1 by miR-128-1 ASO prevents diet-induced obesity (DIO), reduces adipocyte 
hypertrophy and inflammation, prevents liver steatosis and inflammation, increases whole body energy 
expenditure and improves glucose homeostasis.  
(A) Representative picture of DIO mice treated with miR-128-1 ASO or control anti-miR at 18 weeks. (B) Body 
weight, (C) body composition and (D) DIO mouse tissue images from miR-128-1 ASO and control treatment 
groups (n=10 per group). Representative histology data (H&E and IHC) of BAT (E), EPI-WAT (G) and liver (I) 
from the miR-128-1 ASO and control treatment groups (n=6 per group). Expression of marker genes related to 
(F) BAT identity (H) epididymal WAT inflammation and (J) liver steatosis was determined by qRT-PCR from the 
DIO mice. Expression of marker genes in muscle related to glucose homeostasis (K) and energy expenditure 
(L) was determined by qRT-PCR and western blotting (M). (N) whole body energy expenditure differences 
were measured in metabolic cages between the miR-128-1 ASO and control group (n=10 per group). 
Intraperitoneal (IP)-glucose tolerance (O) and insulin tolerance tests (P) were performed after 14 weeks of 
miR-128-1 ASO and control treatment. Error bars represent SEM. Student’s t test, *P<0.05, **P<0.01, 
***P<0.001, compared to mice injected with control ASO.  
 
Figure 4. Anti-miR-128-1 treatment of DIO mice improves hepatic, skeletal muscle, and adipocyte insulin 
sensitivity.  
(A) Body weight and (B) body fat percentage in anti-miR-128-1 treated and control HFD-fed mice. (C) Plasma 
glucose concentrations during the hyperinsulinemic-euglycemic clamp. (D) Glucose infusion rate required to 
maintain euglycemia during the clamp studies. (E) Steady state (100-140 min) glucose infusion rates required 
to maintain euglycemia during the clamp. (F) Insulin-stimulated glucose uptake in skeletal muscle and white 
adipose tissue. (G) Basal and insulin mediated suppression of endogenous glucose production during the 
clamp. (H) Insulin-mediated suppression of plasma NEFA during the clamp. In all panels, data are expressed 
as the mean±SEM of n=7 mice per group, with comparisons by the 2-tailed paired (basal vs. clamp) or 
unpaired (control vs. miR-128-1 ASO) Student’s t-test.  
 
Figure 5. miR-128-1 deficiency prevents adiposity, increases whole body energy expenditure and improves 
glucose homeostasis.  
(A) Body weight and (B) body composition of WT and miR-128-1 KO mice (n=10 per group). (C) Whole body 
energy expenditure and (D) activity differences between miR-128-1 KO and WT mice were measured in 
metabolic cages (n=10 per group). (E) Rectal temperatures of cold (4oC) exposed miR-128-1 KO mice and WT 
animals (n=6 per group). (F) Representative IHC of Ucp1 in BAT KO group were compared to WT mice (n=6 
per group). (G) Energy expenditure differences of brown adipocytes isolated from miR-128-1 KO and WT mice. 
IP-Glucose tolerance (H) and insulin tolerance tests (I) of miR-128-1 KO and WT mice were performed at 10 
weeks of HFD feeding. Error bars represent SEM. Student’s t test, *P<0.05, **P<0.01, ***P<0.001, compared 
to control mice. 
 
Figure 6. Manipulation of miR-128-1 level in primary human adipocytes alters differentiation state, energy 
expenditure and leptin/adiponectin secretion.  
Over-expression of pre-miR-128-1 prevents primary human adipocyte differentiation (A) and reduces adipocyte 
hallmark gene expression (B) anti-miR-128-1 promotes primary human adipocyte differentiation (C) and 
upregulates adipocyte hallmark gene expression (D). Levels of leptin (E) and adiponectin (F) secreted from 
human primary adipocytes treated with miR-128-1 pre-cursor and anti-miR-128-1. (G) Cellular levels of 
adipocyte genes in primary human adipocytes were confirmed by western blotting. FAO changes in primary 
human adipocytes induced by overexpressing miR-128-1 (H) or knockdown (I) was assessed. Errors bars 
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represent mean ± SD. Student’s t-test, *P<0.05, **P<0.01, ***P<0.001, compared to cells transfected with 
control ASO. 
 
Figure 7. miR-128-1 controls primary brown adipocyte differentiation/identity and energy expenditure and 
restricts trans-differentiation of muscle cell to brown adipocyte lineage.  
 (A) miR-128-1 WT and KO primary brown adipocytes were induced to differentiate to mature brown 
adipocytes and stained with Oil-red O. (B) Mitochondrial respiration of miR-128-1 WT and KO brown 
adipocytes was measured by Seahorse analysis. (C-G) Brown adipocyte marker gene expression of miR-128-
1 WT and KO brown adipocytes was measured by qRT-PCR. (H-M) Introduction of miR-128-1 pre-cursor or 
anti-miR-128-1 into mature brown adipocytes. (H, K) Analysis of expression of brown adipose marker genes 
and energy expenditure genes by qRT-PCR. (I-M) The brown adipocyte activator dbcAMP stimulates Pgc-1 
and Ucp-1 expression in mature mouse brown adipocytes. (N) Anti-miR-128-1 induces C2C12 myoblast 
differentiation into brown adipocytes. C2C12 myoblasts were stained with Oil-red O after 8 days of treatment. 
(O-Q) Pan-adipocyte and brown adipose-specific marker expression was determined by qRT-PCR and 
Western blotting. (R) Myotube formation was assessed after 5 days of C2C12 myocyte differentiation by qRT-
PCR analysis of myotube marker gene expression. FAO (S) and mitochondrial respiration (T) were measured 
by Seahorse analysis after induction of brown adipocyte differentiation by anti-miR-128-1 treatment. Errors 
bars represent mean ± SD. Student’s t-test, *P < 0.05, **P < 0.01, ***P < 0.001, compared to WT cells or cells 
transfected with control ASO. 
 
Supplemental Figure and Table Legends 
 
Figure S1. Selection signals at the 2q21.3 locus. Related to Fig. 1. 
(A) Composite of multiple signals (CMS) un-normalized selection signal. Normalization (Grossman et al., 2010) 
corrects for frequency-dependence of CMS values. 
(B) 2q21.3 associations with multiple metabolic traits and positive selection. In each case, the axes show the 2 
Mb section of chromosome 2 surrounding the positively selected region and the associations of all SNPs in the 
region. This region associates with total cholesterol, LDL cholesterol, and 1,5-AG. Furthermore, there is a 
strong signal of positive selection as indicated by singleton density score (Field et al., 2016). 
(C) Effect of the lactase persistence allele at rs41380347 on lipid levels in European-ancestry and African-
ancestry individuals from UK Biobank (Sinnott-Armstrong, Tanigawa et al., 2019) and the Million Veteran 
Program (Klarin et al., 2018). 95% confidence intervals shown. (D) Dramatic selection at 2q21.3 was present in 
European but not African individuals in gnomAD. All variants in gnomAD in the region are showed, with a 
heatmap of counts at different points in the folded site frequency spectrum. The total count of variants 
contained within a given bin of frequencies and positions corresponds to the saturation of the pixels in the 
heatmap. 
 
Figure S2. Allele-specific epigenetic effects of the long European haplotype. Related to Fig. 2. 
(A) Top: Positional patterns of CTCF enrichment around UBXN4 promoter, shown as the heatmap in the 3-Kbp 
proximity of UBXN4 transcription start site (TSS) among the ENCODE samples ranked by the rs1438307 
variant frequency. CTCF enrichment in samples with the highest frequency (marked by red bar; see also red 
boxplot in Fig. 2D) is much higher. Bottom: This stratification of ENCODE samples by CTCF enrichment is not 
due to a systematic bias towards a stronger genome-wide CTCF signal. Distributions of Z-scores of CTCF 
enrichment at all peaks genome-wide (shown as boxplots aligned with the heatmap above) are approximately 
similar in all ENCODE samples, whereas the Z-score for the enrichment of CTCF at the rs1438307 locus 
(shown as red dots) stands out much stronger in the samples with the higher allelic frequency of the variant. 
The color bar shows the SNP allele frequency in individual ENCODE samples, estimated from the CTCF ChIP-
seq reads at the rs1438307 locus. (B) Heatmaps of chromatin interactions in the genomic region of interest, 
derived from a high-resolution Hi-C experiment in the human GM12878 cell line (Rao et al., 2014). Hi-C 
chromatin domain contains the variant, confirming the effect shown in HiChIP. The topological domain 
structure does not appear to be an artifact of the cohesin pull-down used in the HiChIP assay. (C) Heatmap 
showing positional profiles of H3K4me3 ChIP-seq density (normalized by input) profile in the 3-Kbp proximity of 
UBXN4 transcription start site (TSS) among the ENCODE samples ranked by the rs1438307 variant 
frequency. (D) Accessibility in the promoter region upstream of miR-128-1 is altered by genotype at rs1438307. 
Normalized accessibility by the total read depth was averaged for each of the lines with a given genotype at 
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rs1438307 and the window around the miR-128-1 gene was plotted. Just upstream of miR-128-1, there is an 
accessibility peak corresponding to the promoter. This peak is genotype dependent, with the derived T allele at 
rs1438307 having the highest average accessibility. 
 
Figure S3. Role of miR-128-1 expression in regulation of metabolism in humans. Related to Fig. 2. 
(A) Expression of miR-128-1 is higher in visceral than subcutaneous adipose tissue. Using all individuals from 
our starting cohort and correcting for Snord48, age, sex, and batch, there is substantially less expression of 
miR-128-1 in subcutaneous adipose tissue than visceral. (B) This effect was confirmed in our replication cohort 
of matched individuals. (C) Haplotype is a weak eQTL for miR-128-1 expression in adipose tissue. Samples 
were quantified for miR-128-1 and a trend was observed across cohorts (Methods). (D-F) Our well-phenotyped 
replication cohort has significant associations between miR-128-1 expression and fasting glucose (D), HbA1c 
(E), and Triacylglycerol/HDL (F). (G) The fasting glucose association is reproduced in the METSIM cohort, as 
assayed using miRNA-seq. (H) miR-128-1 expression goes up substantially over time in the FANTOM5 time 
course expression data. Secondary association at 2q21.3 has a high posterior probability placed on rs1446585 
as being causal for Apolipoprotein A1 levels (I) and HDL-cholesterol levels (J), as inferred by FINEMAP by the 
Finucane lab. 
 
Figure S4. Pharmacological inhibition of miR-128-1 by anti-miR-128-1 prevents diet-induced obesity (DIO), 
reduces adipocyte hypertrophy and inflammation, prevents liver steatosis and increases whole body energy 
expenditure and improves glucose homeostasis. Related to Fig. 3. 
(A) Adipocyte miR-128-1 levels were determined by qRT-PCR in DIO mice treated with anti-miR-128-1 (n = 10 
per group). (B) food intake of anti-miR-128-1 and control anti-miR treated DIO mice. Plasma triglycerides (C) 
and cholesterol (D) were determined by FPLC analysis. Expression of selected marker genes related to (E) 
BAT identity, (F) WAT inflammation, and (G) liver steatosis was determined by western blotting. Differences 
between the anti-miR-128-1 and control groups (n=10 per group) in whole body oxygen consumption (H) and 
activity (I, J) were measured using metabolic cages. (K) Luciferase activity in HEK293T cells transfected with 3′ 
UTR-luciferase reporters for human PPARGC1, PPARG, PPARA and PRDM16 or reporters harboring point 
mutations in the predicted miRNA target sites, co-transfected with miR-128-1 precursor. Error bars represent 
SEM. Student’s t test, *P < 0.05, **P < 0.01, ***P < 0.001 compared to mice injected with the control ASO. 
 
Figure S5. Pharmacological inhibition of miR-128-1 in leptin-deficient (ob/ob) mice prevents adiposity, reduces 
adipocyte hypertrophy and inflammation, increases the brown appearance of BAT, prevents liver steatosis and 
inflammation, increases whole body energy expenditure and improves glucose homeostasis. Related to Fig. 3. 
(A) Body weight of ob/ob mice treated with anti-miR-128-1 and control anti-miR. (B) Body composition and liver 
and epididymal WAT from ob/ob mice treated with anti-miR-128-1 and control anti-miR (n=10 per group). (C) 
Whole body energy expenditure differences were measured in metabolic cages between the anti-miR-128-1 
and control group (n=10 per group). Representative histology data (H&E) of BAT (D), EPI-WAT (F) and liver 
(H) from the anti-miR-128-1 treated group were compared to the control group (n=6 per group). Expression of 
marker genes related to (E) BAT identity and energy expenditure (G) WAT hypertrophy and inflammation, and 
(I) liver steatosis and energy expenditure were determined by quantitative RT-PCR (qRT-PCR) from the ob/ob 
mice. Intraperitoneal (IP) glucose tolerance (J) and insulin tolerance tests (K) were performed after 10 weeks 
of anti-miR-128-1 and control anti-miR treatment. Error bars represent SEM. Student’s t test, *P < 0.05, **P < 
0.01, ***P < 0.001 compared to mice injected with the control ASO. 
 
Figure S6. Analysis of gene expression in miR-128-1 KO mice and wild-type controls. Related to Fig. 5. 
Quantitative RT-PCR analysis of expression of selected genes involved in metabolic control and inflammation 
in (A) BAT, (B) WAT, (C) skeletal muscle and (D) liver in wild-type and miR-128-1 KO mice. Error bars 
represent SEM. Student’s t test, *P < 0.05, **P < 0.01, ***P < 0.001 compared to WT control mice. 
 
Figure S7. Decreased hypertrophy and increased browning of subcutaneous (inguinal/iWAT) WAT in DIO 
mice treated with anti-miR-128-1. Related to Figs. 3 and 7. 
(A) Representative H&E-stained images of inguinal WAT from DIO mice treated with anti-miR-128-1 for 16 
weeks. (B-D) Lowered expression of lipogenic genes such as Srebf1 (B), Fasn (C), and Acc1 (D) in iWAT from 
mice treated with anti-miR-128-1. (E-J) Increased expression of beneficial WAT genes (E) Pparg, (F) Adipoq, 
and energy expenditure/browning genes (G) Ppargc1a, (H) Prdm16, (I) Ppara, and (J) Ucp1 in anti-miR-128-1 
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treated mice. Error bars represent SEM. Student’s t test, *P < 0.05, **P < 0.01, ***P < 0.001 compared to mice 







RESOURCE AVAILABILITY  
Lead Contact  
Further information and requests for reagents may be directed to, and will be fulfilled by the lead contact 
Anders M. Näär (naar@berkeley.edu). 
Materials Availability 
 
Plasmids generated in this study will be freely distributed.  
Data and Code Availability  
Data sets analyzed: The code supporting the current study has not been deposited in a public repository 
because no novel algorithms or methods were employed, but is available from the corresponding author on 
request. Data employed include GWAS summary statistics and fine-mapped variants derived from the UK 
Biobank resource, Million Veteran Program, Global Lipids Genetics Consortium, and numerous other individual 
supporting studies; whole-genome sequencing data from gnomAD; epigenetic data from the Roadmap 
Epigenomics and ENCODE projects; and expression data from GDSC, CCLE, FANTOM5, ENCODE, and 
Civelek et al., 2013. Selection scores were derived by the Sabeti, Pritchard, and Ostrander labs, as well as the 
Bovine Hapmap Consortium. Underlying data from human subjects used in this study are publicly available, 
either without restriction or through application to dbGaP or the UK Biobank. Restrictions exist on access to 
underlying data from non-human studies. 
Experimental Model and Subject Details 
 
Cell culture and mouse 
Cell lines:  
HepG2, 3T3-L1, C2C12 and HEK293T cells were obtained from the ATCC and propagated according to 
ATCC's instructions.  
Brown pre-adipocytes were received from Dr. Kai Ge, NIDDK/NIH and were routinely cultured in DMEM plus 
10% FBS. 
Primary cells:   
Primary mouse brown adipocytes were isolated from day 1 newborn pups; 
Primary human white adipocytes were obtained from human subjects by surgical resection or subcutaneous 
adipose tissue aspiration and were cultured using regular methods described in Lee and Fried, (2014) in alpha-
MEM with 10% FBS and antibiotics. 
Mice:  
The C57BL/6J and ob/ob mice were purchased from The Jackson Laboratory, Bar Harbor, ME, all were male 
aged at 6-8 weeks. 
miR-128-1 KO mice: experimental manipulation of miR-128-1 in vivo was achieved by crossing mice carrying 
miR-128-1 floxed alleles (Tan et al., 2013) to transgenic Cre-recombinase mouse lines. For germline excision, 
we used the ubiquitously expressed cytomegalovirus-Cre mouse line (CMV-Cre; Jackson Labs #006054). 
Genotyping was performed as described in Wark et al., (2017). Lines were maintained on the C57BL/6J 
background on a 12-hour light-dark cycle with constant access to food and water. Male mice with age from 6 
weeks to 16 weeks were used in different experiments. All experimental procedures were conducted in 
accordance with IACUC regulations and were approved by Massachusetts General Hospital’s or Yale 
University School of Medicine’s IACUC.  
   
Method Details 
 
Mouse miR-128-1 inhibition studies 
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LNA–modified anti-miR oligonucleotides targeting miR-128-1 (5’-TTCACTGTG-3’a; 9-mer), (5’-
GGTTCACTGTG-3’a; 11-mer) and a scrambled control LNA oligonucleotide (5’-TCATACTA-3’) were 
purchased from Exiqon, Denmark (now Qiagen). The 9-mer LNA ASO was used in all in vivo studies except in 
the hyperinsulinemic-euglycemic studies at Yale University School of Medicine, where we used the second-
generation 11-mer LNA ASO. Experiments were performed using 7-week-old male C57BL/6J mice or ob/ob 
mice purchased from The Jackson Laboratory, Bar Harbor, ME. The diet-induced obese (DIO) mice were fed a 
diet containing 60% (kcal) fat (D12492, Research Diets) for 6 weeks before and during treatment. The 
longitudinal studies were performed in mice fed with the high-fat diet for 16 weeks, or chow-fed ob/ob mice, 
with once-weekly subcutaneous injection of the anti-miR-128-1 (10 mg/kg) or control scrambled LNA 
oligonucleotide. Body weight was measured every week. During the treatment, glucose and insulin tolerance 
tests are performed at around week 10 and body composition was measured at 14 weeks. Metabolic activity of 
the mice was analyzed in metabolic cages at around week 15 and data were collected for one week. Upon 
sacrifice, brown and white (inguinal and epididymal, respectively) adipose tissue and livers were collected and 
∼1 ml of blood was obtained from each mouse by right ventricular puncture. Blood was centrifuged at 8,000 
rpm for 5 min to obtain serum, which was frozen at −80°C. Total serum cholesterol and triglyceride levels were 
determined with a Heska Dri-Chem 4000 Chemistry Analyzer (Heska, Loveland, CO) at Massachusetts 
General Hospital, Center for Comparative Medicine, Diagnostic Laboratory. FPLC analysis of pooled serum 
was carried out as described (Wagschal et al., 2015), the area under the curve (AUC) was calculated using the 
linear trapezoidal method based on a linear interpolation between data points. The AUC was calculated as 
follows: AUC = 1/2 (C1+C2), where C indicates the concentration of lipids in two incremental FPLC fractions. 
The average AUC value for the VLDL, LDL or HDL fractions was calculated and indicated with the SEM 
and P value. All mouse procedures were approved by the Massachusetts General Hospital or Yale University 
School of Medicine Institutional Animal Care and Use Committees. 
 
Tissue sample preparation and gene expression measurement 
All tissue samples were rapidly dissected, snap frozen in liquid nitrogen, and stored at −80°C until mRNA and 
protein extraction. Western blotting was performed using standard protocol (Wagschal et al., 2015), briefly, 
cells or tissues were lysed in RIPA buffer (0.5% NP-40, 0.1% SDS, 150 mM NaCl, 50 mM Tris-HCl (pH 7.5)). 
Proteins were separated by SDS–PAGE, transferred to nitrocellulose membrane (Millipore) and probed with 
antibodies of the respective targets. For mRNA and miRNA quantification, TRIzol (Life 
Technologies/Invitrogen) was used for total RNA and miRNA extraction from either mouse tissues or cells. For 
miRNA extraction from human tissues mirVana™ miRNA Isolation Kit, with phenol (ThermoFisher Scientific 
Cat# AM1560) was used. The high Capacity cDNA Reverse Transcription Kit and the TaqMan MicroRNA 
Reverse Transcription Kit (Life Technologies/Invitrogen) were used for further reverse transcription. cDNA was 
further evaluated by real-time PCR for gene expression using Power SYBR Green or Taqman PCR Master Mix 
with ABI 7500 Real-Time PCR System The amount of the indicated mRNA or miRNA was normalized to the 
amount of 18S and U6 RNA, respectively. Total RNA for miRNA expression levels analysis in human tissues 
was purchased from Ambion (FirstChoice Human Total RNA Survey Panel, AM6000). To quantify miR-128-1 
levels, RNAs were reverse transcribed using the TaqMan MicroRNA Reverse Transcription Kit and quantified 
with the miRNA-specific TaqMan miRNA assays (Life Technologies/Invitrogen). PCR primer sequences are 
available from A.M.N. upon request. 
 
Histology 
Adipose and liver tissues from each study animal were sectioned for histology (Lillie and Fulmer, 1976). 
Paraffin-embedded sections were prepared for H&E and IHC, respectively and the samples were processed in 
the histology core facility of MGH. The completed slides were examined and representative pictures were 
taken. 
 
Metabolic cage housing and energy expenditure measurements 
After 15-16 weeks of treatment, mice were individually housed and maintained under otherwise standard 
housing conditions (12-hour light-dark cycle). The 240 LabMaster System (TSE Systems, Chesterfield, MO) 
was used to measure the calorimetry indirectly. Mice were provided ad libitum access to food and water with a 
4-day acclimation period. Oxygen consumption, energy expenditure, activity (X-Y-axis movement activity and 
Z-axis 245 rearing activity), as well as food/ water consumption were monitored in consecutive light-dark cycles 




Male mice underwent surgery under general isoflurane anesthesia to implant a polyethylene catheter in the 
right jugular vein. After a one-week recovery period, mice were fasted overnight (14 hr) and underwent a 
hyperinsulinemic-euglycemic clamp as previously described (Jurczak et al., 2012). Briefly, mice received a 
basal infusion of [3-3H] glucose (0.05 Ci/min) for 120 min, after which blood samples were taken from the tail 
vein, centrifuged, and plasma stored at -80°C for further analysis. A 140 min hyperinsulinemic-euglycemic 
clamp was then initiated: mice were infused with insulin (3.0 mU/[kg-min]) and [3-3H] glucose (0.1 Ci/min). 
Blood samples were obtained from the tip of the tail at 0, 25, 45, 65, 80, 90, 110, 120, 130, and 140 min for 
plasma glucose measurements. To evaluate insulin-stimulated tissue-specific glucose uptake, a 10 Ci bolus 
of 2-deoxy-d-[1-14C] glucose (PerkinElmer) was injected after 85 minutes. After IV pentobarbital euthanasia, 
skeletal muscle (gastrocnemius + soleus) and epididymal white adipose tissue were isolated, and tissue [14C] 
2-deoxyglucose specific activity was measured. 
 
Biochemical analysis 
Plasma glucose concentrations were measured using the YSI Glucose Analyzer, and NEFA using an 
enzymatic assay (Wako Diagnostics HR Series NEFA-HR(2)). Plasma insulin was measured by 
radioimmunoassay by the Yale Diabetes Research Center. Basal and clamp endogenous glucose turnover 
were calculated by measurement of steady-state plasma [3H] glucose enrichment at the end of the basal and 
clamp periods. Tissue 2-deoxyglucose uptake was calculated following measurement of plasma and tissue 
[14C] 2-deoxyglucose specific activity as previously reported (Youn and Buchanan, 1993). 
 
Seahorse 
Brown and white pre-adipocytes and C2C12 cells were plated in gelatin-coated XF24-well cell culture 
microplates (Seahorse Bioscience) and brown and white pre-adipocytes were then differentiated into 
adipocytes. Oxygen consumption and mitochondrial function were measured by XF24 Extracellular Flux 
Analyzer (Seahorse Biosciences) as described previously (Ahfeldt et al., 2012). 
 
Intraperitoneal glucose tolerance test and insulin tolerance test 
Mice were fasted for 12 hours before the tests. For glucose tolerance test, 1.5 mg/g D-(+)-glucose (G7528, 
Sigma Aldrich) was injected intra-peritoneally into the mice and the glucose levels were measured at 0 (before 
injection), 30, 60, and 120 min post-injection. For insulin tolerance test (ITT), 0.00075 U/g insulin (I9278-5 ML, 
Sigma Aldrich) was used for intra-peritoneal injection and the glucose levels were measured at 0 (before 
injection), 15, 45 and 60 min after injection. 
 
Adipocyte and myocyte differentiation and Oil-red O staining 
Brown and white pre-adipocytes were differentiated and Oil-red O-stained as described (Wang et al., 2010). 
Briefly, cells were plated at a density of 5 × 105 per 10-cm dish in differentiation medium (DMEM plus 10% 
FBS, 0.1 μM insulin, and 1 nM T3) 4 days before induction of adipogenesis. At day 0, cells were fully confluent 
and were treated with differentiation medium supplemented with 0.5 mM 3-isobutyl-1-methyl-xanthine (IBMX), 
2 μg/mL dexamethasone, and 0.125 mM indomethacin. Two days later, cells were changed to the 
differentiation medium. The medium was replenished at 2-day intervals. At day 3–4, small lipid droplets 
appeared in differentiating cells. At day 6–8 postinduction, fully differentiated cells were either stained with Oil 
Red O or subjected to gene expression analysis by qRT-PCR or Western blot. Myocyte differentiation and 
staining were conducted as described (Sun et al., 2011). Briefly, to induce myoblasts for adipogenesis, C2C12 
myoblasts or primary human myoblasts were infected as described below, cultured to confluence, and then 
exposed to brown adipocyte differentiation conditions: 10%FBS DMEM, Insulin 850 nM (Sigma), 
Dexamethasone 0.5 µM (Sigma), IBMX 250 µM (Sigma), Rosiglitazone 1uM (Cayman Chemical), T3 1 nM 
(Sigma), and Indomethacin 125 nM (Sigma). After 2 days, cells were incubated in culture medium containing 
insulin 160nM and Rosiglitazone 1 µM for another 2 days, and then were switched to 10% FBS DMEM. To 
stimulate thermogenesis, cells were incubated with dibutyryl cAMP at 0.5 mM (Sigma) for 4 h. 
 
Fatty acid beta-oxidation analysis 
Fatty acid beta-oxidation was assessed by using 14C-Palmitate with the methods described in Antinozzi et al., 




Cells were obtained from the ATCC and propagated according to ATCC's instructions. Transfection of 
antisense and precursor oligonucleotides (35 nM final concentration) was performed in mammalian cells using 
Lipofectamine RNAiMAX Reagent (Life Technologies/Invitrogen. Plasmid transfection in HEK293T cells was 
performed with Lipofectamine 2000 (Life Technologies/Invitrogen) according to the manufacturer's instructions. 
 
Luciferase assays  
Luciferase plasmids harboring the 3’ UTRs of PPARG, PPARA, PPARGC1A and PRDM16 were purchased 
from GeneCopoeia. Mutagenesis of the 3’ UTRs was performed with the QuikChange II XL Site-Directed 
Mutagenesis Kit (Stratagene) according to the manufacturer's instructions. Luciferase activity was measured 
according to the manufacturer's protocol (Promega, Madison, WI) and was normalized to β-galactosidase 
activity. 
 
Quantification and statistical analysis  
 
1. In vitro/in vivo experiments  
Statistical parameters and details are reported in each figure legend. Generally, in vitro experiments were 
repeated at least three times and histograms represent mean ± SD unless specified. Luciferase assays were 
performed in quadruplicate starting from four biological replicates, and error bars represent the SD. qRT-PCR 
analyses were carried out in triplicate or duplicate sets and the error bars represents the SD. The number and 
age of animals used in each mouse study follows the pertinent literature of comparable studies in which the 
desired effect sizes were considered to be significant, and details could be found in each individual figure 
legend. There were no mice excluded in the analyses. Error bars in mouse studies indicate SEM. For both in 
vitro and in vivo studies, the unpaired two-sided Student's t-test was used for statistical differences. P ≤ 0.05 
was considered as statistically significant. Data analysis was performed using Excel Software Version 14.4.5.  
 
2. Human quantification and statistical analysis  
 
2.1 GWAS summary statistics 
For Figure S1B in which summary statistics were reported, SNPs were merged by rsid with HapMap3 SNPs, 
filtered for strand ambiguity and alleles being different than in HapMap3, and tested for genomic position and 
p-value. All reported SNPs within the window were included in the locuszoom plot. Total cholesterol and LDL 
were downloaded from the GLGC website (http://lipidgenetics.org/); 1,5-Anhydroglucitol from the metabolomics 
server (http://gwas.eu/); and singleton density score from the Pritchard lab website 
(http://web.stanford.edu/group/pritchardlab/home.html). Plots were generated in R using ggplot2. 
 
2.2 PheWAS plots 
The UK Biobank-wide PheWAS plot was downloaded from the Oxford BIG Server (http://big.stats.ox.ac.uk/, 
Elliot et al. 2018 = https://pubmed.ncbi.nlm.nih.gov/30305740/). For this analysis, the PheWAS for rs1438307 
was directly queried, and the resulting associations were filtered to name relevant traits in the figure. 
 
2.3 Ancient DNA analysis 
The ancient DNA analysis with estimated allele frequency trajectories and selection coefficients in ifferent 
ancient European populations was carried out as described (Mathieson and Mathieson, 2018).  
 
2.4 eQTL analysis 
Individuals from our cohorts were compared based on genotype at rs1446585 (the SNP which was present in 
all datasets). A linear model of the form mir128_Ct ~ control_RNA_Ct + age + sex + batch + Tissue + sex * 
Tissue + age^2 was set up in R to correct for common confounders in these regressions, to which a term for 
genotype dosage was added. An ANOVA F-test was used to evaluate significance (p = 0.06). Inverse-variance 
weighted meta-analysis was used for combining individual dosage test statistics across cohorts. 
 
2.5 Roadmap epigenome and Hi-C analysis 
Data from the 127 reference epigenomes was visualized using the WashU epigenome browser focused on the 
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region, together with CTCF in a few cell types. Both Hi-C and Hi-ChIP data, normalized by the browser, were 
reported as annotated in the WashU browser. 
 
2.6 gnomAD analysis 
The chromosome 2 VCF was downloaded from the gnomAD website (http://gnomad.broadinstitute.org/) and 
reported allele frequency was folded (AF = min(AF, 1-AF)) and subset to either African or non-Finnish 
European as designated by gnomAD (Karczewski et al., 2020), then plotted using R and ggplot2. 
 
2.7 Expression correlation analysis 
Matched expression data for cell lines in GDSC and CCLE were downloaded from CellMinerCDB 
(https://discover.nci.nih.gov/cellminercdb/) and plotted using R and ggplot2. 
 
2.8 FANTOM analysis 
FANTOM time course miRNA data were downloaded from the FANTOM website (http://fantom.gsc.riken.jp/5) 
and promoters were assigned to genes based on the calls from the miRNA paper (deRie et al., 2017). 
Expression was plotted over time using ggplot2 in R, with error ribbons as 95% confidence intervals using the 
loess model. 
 
2.9 METSIM miRNA analysis 
The METSIM calls did not distinguish between miR-128-1 and miR-128-2, as only mature miRNA sequences 
were used. To overcome this, we downloaded the raw METSIM miRNA-seq data from SRA (linked from GEO 
GSE45159, Civelek et al., 2013), took miRNA hairpin sequences from the miRBase (http://www.mirbase.org/) 
and aligned to the human orthologs and quantified using Kallisto (Bray et al., 2016). We filtered out any 
samples with fewer than 500,000 total mapped reads. Clinical data were downloaded from individual GEO 
pages and used to compare fasting glucose levels to the measured expression with R. 
 
2.10 Read count analyses 
Raw BAMs from the CATO project (Maurano et al., 2015: https://resources.altius.org/publications/CATO/) were 
downloaded and filtered to those with at least 10 reads covering the rs1438307 variant. Lines with 1 or 2 
reference or alternative alleles were excluded due to the potential for miscalling. Each line's position was 
calculated based on the total reference + alternative read count versus their log2 ratio. Thus, the non-
reference, non-alternative reads were ignored, as was the read quality (beyond that which was performed in 
Maurano et al., 2015). The processed genotype calls were then aggregated by genotype, scaled on a per-line 
basis by the total read depth in the filtered BAM file. Then each call was scaled by the number of lines with the 
given genotype to avoid scale differences due to the number of datasets included. Data were output as a 
bigWig track to the WashU browser after being converted using deeptools at 25 bp resolution. 
 





UCP1 Abcam ab23841 
F4/80 Novus biologicals NB600-404 
TNF alpha Abcam ab6671 
CD36 Abcam ab133625 
PGC1 alpha Abcam ab54481 
CPT1B Abcam ab134988 
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PPAR alpha Abcam ab24509 
UCP3 Abcam ab3477 
Insulin Receptor Abcam ab137747 
IRS1 Abcam ab52167 
β-Tubulin Sigma T8328 
AMPK alpha 2 Abcam ab3760 
AMPK alpha 2 (phospho S491) Abcam ab109402 
PPAR gamma Abcam ab45036 
Acetyl-CoA Carboxylase Cell Signaling #3662 
Phospho-Acetyl-CoA 
Carboxylase 
Cell Signaling #3661 
PRDM16 Abcam ab202344 
SIRT1 Abcam ab12193 
IL-1β (3A6) Cell Signaling #12242 
SREBP1 Novus biologicals NB100-2215 
SREBP1 (Phospho-S439) Biorbyt orb315711 
Chemicals, Peptides, and Recombinant Proteins 
Taqman PCR Master Mix, no 
AmpErase UNG  
Applied Biosystems Cat# 4324018 
PALMITIC ACID, [1-14C]-, 50 
µCi 
Perkin Elmer NEC075H050UC 
Dexamethasone Sigma D4902 
Indomethacin Sigma I7378 
3-Isobutyl-1-methylxanthine Sigma I7018 
Insulin Sigma I2643 
Oil Red O Sigma O0625 
Dibutyryl cyclic-AMP Sigma D0260 
AICAR Sigma A9978 
   
   
Critical Commercial Assays 





Roche  Cat# 03531287001 
RNeasy Plus Mini Kit QIAGEN Cat# 74134 
Pierce BCA Protein Assay Kit Thermo Scientific Cat# 23225 
Seahorse Bioassay Agilent Technologies Cat# 102416 
QuikChange™ Site-Directed 
Mutagenesis Kit 
Agilent Technologies Cat# 200518 
Experimental Models: Cell Lines and Primary cells 
HepG2 ATCC ATCC® HB-8065™ 
3T3L1 Dr. Kai Ge ATCC® CL-173™ 
C2C12 ATCC ATCC® CRL-1772™ 
Brown preadipocytes Dr. Kai Ge Wang et al., 2010 
Primary human white 
preadipocyte 
Dr. Susan K. Fried  
Primary preadipocytes This study  
Recombinant DNA 
PPARg GeneCopoeia MmiT054223 
PPARa GeneCopoeia MmiT029952 
PGC1a GeneCopoeia MmiT055331 
PRDM16 GeneCopoeia MmiT035098 
Oligonucleotides 
PPARa-3’ UTR muta cagagtggtttgtttgtttgtttttgttttaaaaatcgtatcattaagatatagctatgaagagcattctttttcattc 
gaatgaaaaagaatgctcttcatagctatatcttaatgatacgatttttaaaacaaaaacaaacaaacaaaccactctg 
PGC1a-3’UTR muta Atattttgatgggctacccatcgcttctgcataagatacacaagcttcactaattttagatgca 
tgcatctaaaattagtgaagcttgtgtatcttatgcagaagcgatgggtagcccatcaaaatat 
PPARg-3’UTR muta Ctaaaactttttgtttttaaatgctttttcatattaaatttcttaggtgtcagatttttttccctcaaaataat 
attattttgagggaaaaaaatctgacacctaagaaatttaatatgaaaaagcatttaaaaacaaaaagttttag 
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